Assembly Biosciences, Inc. (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total value of $29,550.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Assembly Biosciences, Inc. (ASMB) traded up $1.67 during trading on Friday, hitting $30.25. The company had a trading volume of 142,723 shares, compared to its average volume of 99,500. Assembly Biosciences, Inc. has a 12-month low of $11.07 and a 12-month high of $36.31.

WARNING: “Assembly Biosciences, Inc. (ASMB) Director William R. Ringo Sells 1,000 Shares” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/assembly-biosciences-inc-asmb-director-william-r-ringo-sells-1000-shares/1678906.html.

Institutional investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors acquired a new stake in shares of Assembly Biosciences during the second quarter worth about $161,000. Parametric Portfolio Associates LLC lifted its holdings in shares of Assembly Biosciences by 13.6% during the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 1,203 shares during the period. Legal & General Group Plc acquired a new stake in shares of Assembly Biosciences during the second quarter worth about $212,000. Wells Fargo & Company MN acquired a new stake in shares of Assembly Biosciences during the second quarter worth about $213,000. Finally, Trexquant Investment LP acquired a new stake in shares of Assembly Biosciences during the second quarter worth about $217,000. 72.41% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have recently weighed in on ASMB shares. BidaskClub upgraded Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 3rd. Zacks Investment Research lowered Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.